NeuroDerm Ltd. (NDRM) Sees Unusually-High Trading Volume
NeuroDerm Ltd. (NASDAQ:NDRM) saw strong trading volume on Monday . 176,795 shares changed hands during trading, an increase of 70% from the previous session’s volume of 103,844 shares.The stock last traded at $16.99 and had previously closed at $17.51.
Several equities analysts have recently issued reports on the stock. Roth Capital reiterated a “buy” rating on shares of NeuroDerm in a report on Sunday, May 29th. Oppenheimer Holdings Inc. reiterated an “outperform” rating and set a $24.00 target price on shares of NeuroDerm in a report on Friday, April 1st. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. NeuroDerm presently has a consensus rating of “Buy” and an average target price of $24.70.
The firm has a 50-day moving average price of $16.92 and a 200 day moving average price of $15.35. The stock’s market capitalization is $368.00 million.
NeuroDerm (NASDAQ:NDRM) last posted its quarterly earnings results on Thursday, May 26th. The company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.10. Equities research analysts anticipate that NeuroDerm Ltd. will post ($1.52) earnings per share for the current year.
NeuroDerm Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in developing treatments for central nervous system (CNS) disorders, primarily Parkinson’s disease, as well as other CNS diseases. The Company is developing ND0612H for the treatment of patients suffering from severe Parkinson’s disease; ND0612L for the treatment of patients at the moderate stage of Parkinson’s disease that can no longer control motor complications with oral levodopa, and ND0680 for the treatment of a small subset of severe Parkinson’s disease patients, whose symptoms have advanced to a severe stage, requiring even higher doses of LD/CD than ND0612H is designed to provide.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.